Basic Stats
| CIK | 881890 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Abaxis, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 27, 2018 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) July 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| August 10, 2018 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS 1 d460595ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. 333-214680 Registration No. 333-199518 Registration No. 333-171316 Registration No. 333-156496 Registration No. 333-131703 Registration No. 333-112815 Registration No. 333-102185 Registration No. 333-84356 Registration No. 333-65812 Registration No. 333-85131 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. |
|
| July 31, 2018 |
S-8 POS 1 d460595ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. 333-214680 Registration No. 333-199518 Registration No. 333-171316 Registration No. 333-156496 Registration No. 333-131703 Registration No. 333-112815 Registration No. 333-102185 Registration No. 333-84356 Registration No. 333-65812 Registration No. 333-85131 Registration No. |
|
| July 31, 2018 |
Amended and Restated Bylaws of Abaxis, Inc. EX-3.2 Exhibit 3.2 BYLAWS of ABAXIS, INC. A California Corporation ARTICLE I OFFICES Section 1.1 Principal Executive Office. The board shall have the power to designate and change the principal executive office from one location to another, within or without the State of California. Section 1.2 Other Offices. Other business offices may be established by the board at any place where the Corporation |
|
| July 31, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): July 31, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 31, 2018 |
Amended and Restated Certificate of Incorporation of Abaxis, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ABAXIS, INC. Clinton H. Severson and Ross Taylor certify that: 1. They are the duly elected and acting Chairman and Chief Executive Officer and Secretary, respectively, of Abaxis, Inc., a California corporation (the “Corporation”). 2. The Articles of Incorporation of the Corporation are amended and restated to read in their entir |
|
| July 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of regi |
|
| July 23, 2018 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| July 6, 2018 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| June 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19720 A. Full title of the plan |
|
| June 27, 2018 |
DEFM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| June 8, 2018 |
ABAX / Abaxis, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 15)* Abaxis, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 002567105 (CUSIP Number) Eddie C. Brown Brown Capital Management, |
|
| June 5, 2018 |
PREM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, fo |
|
| May 31, 2018 |
Conflict Minerals Report For The Year Ended December 31, 2017 Exhibit 1.01 Conflict Minerals Report For The Year Ended December 31, 2017 This Conflict Minerals Report (this “Report” or “CMR”) of Abaxis, Inc. (“Abaxis,” “our,” “us,” or “we”), for the period from January 1, 2017 through December 31, 2017 (the “Reporting Period”) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities |
|
| May 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3240 Whipple Road Union City, CA 94587 (Address of principal executive offices, i |
|
| May 30, 2018 |
EXHIBIT 21.1 SUBSIDIARIES OF ABAXIS, INC. The following is a list of subsidiaries of the Registrant, omitting some subsidiaries that, considered in the aggregate, would not constitute a significant subsidiary. Name Jurisdiction of Incorporation Abaxis Asia Hong Kong Abaxis Europe GmbH Germany Abaxis UK England |
|
| May 30, 2018 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of regis |
|
| May 18, 2018 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| May 17, 2018 |
EX-99.1 Exhibit 99.1 Dear , Today Abaxis announced it has entered into an agreement to be acquired by Zoetis, a leading animal health company with global scale in the discovery, development, manufacture and marketing of veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Once the acquisition is complete, we look forward to our |
|
| May 17, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 d573559d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 16, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation |
|
| May 17, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 16, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| May 17, 2018 |
Customer Letter first used or made available on May 16, 2018 EX-99.1 2 d573559dex991.htm EX-99.1 Exhibit 99.1 Dear , Today Abaxis announced it has entered into an agreement to be acquired by Zoetis, a leading animal health company with global scale in the discovery, development, manufacture and marketing of veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Once the acquisition is compl |
|
| May 16, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 d553493d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 16, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation |
|
| May 16, 2018 |
EX-99.1 Exhibit 99.1 FROM: CLINT SEVERSON, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ABAXIS TO: ALL ABAXIS COLLEAGUES Dear Abaxis Colleagues, Today we announced that Abaxis has entered into a definitive merger agreement with Zoetis, a leading animal health company, pursuant to which Zoetis will acquire Abaxis. This is a tremendous opportunity for both Abaxis and Zoetis. By leveraging Zoetis’ scale in |
|
| May 16, 2018 |
EX-99.2 Exhibit 99.2 INTRODUCING YOU TO ZOETIS May 16, 2018 FORWARD-LOOKING STATEMENTS Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Excha |
|
| May 16, 2018 |
Employee Letter from Clinton H. Severson to Company employees on May 16, 2018 EX-99.1 2 d553493dex991.htm EX-99.1 Exhibit 99.1 FROM: CLINT SEVERSON, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ABAXIS TO: ALL ABAXIS COLLEAGUES Dear Abaxis Colleagues, Today we announced that Abaxis has entered into a definitive merger agreement with Zoetis, a leading animal health company, pursuant to which Zoetis will acquire Abaxis. This is a tremendous opportunity for both Abaxis and Zoetis. By |
|
| May 16, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 16, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| May 16, 2018 |
Town Hall Presentation delivered by Parent to Company employees on May 16, 2018 EX-99.2 3 d553493dex992.htm EX-99.2 Exhibit 99.2 INTRODUCING YOU TO ZOETIS May 16, 2018 FORWARD-LOOKING STATEMENTS Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933 and Section |
|
| May 16, 2018 |
EX-99.1 3 d588957dex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE: May 16, 2018 Zoetis Media Contacts: Zoetis Investor Contact: Elinore White Steve Frank 1-973-443-2835 (o) 1-973-822-7141 (o) [email protected] [email protected] Bill Price Abaxis Media & Investor Contact: 1-973-443-2742 (o) Clint Severson [email protected] 510-675-6500 (o) Zoetis to Acquire Abaxis, a Leadi |
|
| May 16, 2018 |
EX-2.1 2 d588957dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among ZOETIS INC., ZEUS MERGER SUB, INC. and ABAXIS, INC. dated as of May 15, 2018 TABLE OF CONTENTS ARTICLE I THE MERGER 1 SECTION 1.01 The Merger 1 SECTION 1.02 Closing 1 SECTION 1.03 Effective Time 2 SECTION 1.04 Effects of the Merger 2 SECTION 1.05 Articles of Incorporation and Bylaws of the Surv |
|
| May 16, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 15, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| May 16, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): May 15, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| May 16, 2018 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among ZOETIS INC., ZEUS MERGER SUB, INC. and ABAXIS, INC. dated as of May 15, 2018 TABLE OF CONTENTS ARTICLE I THE MERGER 1 SECTION 1.01 The Merger 1 SECTION 1.02 Closing 1 SECTION 1.03 Effective Time 2 SECTION 1.04 Effects of the Merger 2 SECTION 1.05 Articles of Incorporation and Bylaws of the Surviving Company 2 SECTION 1. |
|
| May 16, 2018 |
Joint Press Release, dated May 16, 2018 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE: May 16, 2018 Zoetis Media Contacts: Zoetis Investor Contact: Elinore White Steve Frank 1-973-443-2835 (o) 1-973-822-7141 (o) [email protected] [email protected] Bill Price Abaxis Media & Investor Contact: 1-973-443-2742 (o) Clint Severson [email protected] 510-675-6500 (o) Zoetis to Acquire Abaxis, a Leading Global Provider of Veteri |
|
| April 26, 2018 |
8-K 1 form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 21, 2018 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) |
|
| April 26, 2018 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2018 and Declares a 13% Increase in Quarterly Cash Dividend Union City, California – April 26, 2018 - Abaxis, Inc. (Nasdaq: ABAX), a glob |
|
| April 26, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 26, 2018 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 27, 2018 |
ABAX / Abaxis, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment SC 13G/A 1 a18-71131sc13ga.htm SC 13G/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . .10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Abaxis, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Numb |
|
| February 14, 2018 |
ABAX / Abaxis, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 14)* Abaxis, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2017 (Date of Event Which |
|
| February 13, 2018 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 9, 2018 |
ABAX / Abaxis, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2017 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as |
|
| February 8, 2018 |
ABAX / Abaxis, Inc. / VANGUARD GROUP INC Passive Investment abaxisinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7 )* Name of issuer: Abaxis Inc Title of Class of Securities: Common Stock CUSIP Number: 002567105 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropriate box to designate th |
|
| January 25, 2018 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend Union City, California – January 25, 2018 - Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics com |
|
| January 25, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 25, 2018 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 9, 2018 |
Abaxis Reports Preliminary Financial Performance for the Third Quarter of Fiscal 2018 EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Preliminary Financial Performance for the Third Quarter of Fiscal 2018 Union City, California – January 9, 2018 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point |
|
| January 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 9, 2018 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Num |
|
| December 8, 2017 |
ABAX / Abaxis, Inc. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* ABAXIS INC (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) November 30, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| November 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 29, 2017 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File N |
|
| November 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant a |
|
| October 30, 2017 |
Abaxis 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 25, 2017 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| October 24, 2017 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend Union City, California – October 24, 2017 - Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics co |
|
| October 24, 2017 |
Abaxis 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 21, 2017 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 19, 2017 |
DEF 14A 1 h10046458x1def14a.htm DEF 14A TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☑ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| September 7, 2017 |
Abaxis SC 13G/A (Passive Acquisition of More Than 5% of Shares) UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D. |
|
| August 9, 2017 |
Piccolo National Accounts Pricing Grid [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. |
|
| August 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as spe |
|
| August 9, 2017 |
SECOND AMENDMENT TO THE EXCLUSIVE AGREEMENT BETWEEN ABBOTT POINT OF CARE INC. AND ABAXIS, INC. EX-10.26 2 ex1026.htm EXHIBIT 10.26 EXHIBIT 10.26 SECOND AMENDMENT TO THE EXCLUSIVE AGREEMENT BETWEEN ABBOTT POINT OF CARE INC. AND ABAXIS, INC. This Second Amendment (“Second Amendment”) to that certain Exclusive Agreement (“Agreement”) dated as of March 7, 2017, is effective as of April 19, 2017 (“Amendment Effective Date”) between Abaxis, Inc. (“ABAXIS”) and Abbott Point of Care Inc. (“ABBOTT”) |
|
| July 28, 2017 |
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31.3 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Clinton H. Severson, certify that: 1. I have reviewed this Amendment to the Annual Report on Form 10-K/A of Abaxis, Inc. and 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements |
|
| July 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of regi |
|
| July 27, 2017 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the First Quarter of Fiscal 2018 and Declares Quarterly Cash Dividend Union City, California ? July 27, 2017 - Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturing point-of-care blo |
|
| July 27, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 27, 2017 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 26, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19720 A. Full title of the plan |
|
| May 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3240 Whipple Road Union City, CA 94587 (Address of principal executive offices, i |
|
| May 31, 2017 |
Conflict Minerals Report For The Year Ended December 31, 2016 Exhibit 1.01 Conflict Minerals Report For The Year Ended December 31, 2016 This Conflict Minerals Report (this ?Report? or ?CMR?) of Abaxis, Inc. (?Abaxis,? ?our,? ?us,? or ?we?), for the period from January 1, 2016 through December 31, 2016 (the ?Reporting Period?) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securities |
|
| May 30, 2017 |
10-K 1 h10044154x110k.htm 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABA |
|
| May 30, 2017 |
EX-21.1 2 h10044154x1ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 SUBSIDIARIES OF ABAXIS, INC. The following is a list of subsidiaries of the Registrant, omitting some subsidiaries that, considered in the aggregate, would not constitute a significant subsidiary. Name Jurisdiction of Incorporation Abaxis Asia Hong Kong Abaxis Europe GmbH Germany Abaxis UK (formerly Quality Clinical Reagents Limited) Englan |
|
| April 27, 2017 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2017 and Declares Quarterly Cash Dividend Union City, California – April 27, 2017 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics c |
|
| April 27, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 27, 2017 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 26, 2017 |
8-K 1 form8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 20, 2017 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) |
|
| February 14, 2017 |
ABAX / Abaxis, Inc. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* ABAXIS INC (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 9, 2017 |
Abaxis ABAXIS, INC. 10-Q 12-31-2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2016 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as |
|
| February 9, 2017 |
ABAX / Abaxis, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment SC 13G/A 1 a17-39861sc13ga.htm SC 13G/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . .10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Abaxis, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Numb |
|
| February 9, 2017 |
ABAX / Abaxis, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 13)* Abaxis, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2016 (Date of Event Which |
|
| February 9, 2017 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2017 |
Abaxis 3G/A (Passive Acquisition of More Than 5% of Shares) abaxisinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6 )* Name of issuer: Abaxis Inc Title of Class of Securities: Common Stock CUSIP Number: 002567105 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropriate box to designate th |
|
| January 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): January 25, 2017 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| January 26, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k.htm ABAXIS, INC. 8-K 1-26-2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 26, 2017 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisd |
|
| January 26, 2017 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2017, Declares Quarterly Cash Dividend Union City, California ? January 26, 2017 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care b |
|
| January 10, 2017 |
Abaxis Reports Preliminary Financial Performance for the Third Quarter of Fiscal 2017 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Preliminary Financial Performance for the Third Quarter of Fiscal 2017 Union City, California ? January 10, 2017 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instrume |
|
| January 10, 2017 |
Abaxis ABAXIS, INC 8-K 1-10-2017 (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 10, 2017 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 17, 2016 |
Abaxis ABAXIS, INC. S-8 11-17-2016 As Filed with the Securities and Exchange Commission on November 17, 2016 Registration No. |
|
| November 9, 2016 |
Abaxis ABAXIS, INC 10-Q 9-30-2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant a |
|
| November 1, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 26, 2016 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| November 1, 2016 |
ABAXIS, INC. 2014 EQUITY INCENTIVE PLAN Exhibit 10.1 ABAXIS, INC. 2014 EQUITY INCENTIVE PLAN Abaxis, Inc. 2014 Equity Incentive Plan Adopted by the Board of Directors: July 23, 2014 Approved by the Shareholders: October 22, 2014 Amended by the Board of Directors: July 20, 2016 Approved by the Shareholders: October 26, 2016 1. General. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuat |
|
| November 1, 2016 |
Abaxis Declares Quarterly Cash Dividend Dividend Increase of 17% Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Declares Quarterly Cash Dividend Dividend Increase of 17% Union City, California ? October 28, 2016 ? The Board of Directors of Abaxis, Inc. (NasdaqGS: ABAX), has declared a cash dividend of $0.14 per common share. The dividend will b |
|
| October 25, 2016 |
Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2017 EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2017 Union City, California – October 25, 2016 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care b |
|
| October 25, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k.htm ABAXIS, INC 8-K 10-25-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 25, 2016 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisd |
|
| September 15, 2016 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 9, 2016 |
Abaxis ABAXIS, INC. 10-Q 6-30-2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as spe |
|
| July 29, 2016 |
Abaxis FORM 10-K/A (Annual Report) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of regi |
|
| July 21, 2016 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the First Quarter of Fiscal 2017 and Declares a Quarterly Cash Dividend Union City, California ? July 21, 2016 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care |
|
| July 21, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 form8k.htm ABAXIS, INC. 8-K 7-21-2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 21, 2016 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdict |
|
| June 28, 2016 |
Abaxis ABAXIS, INC. 11-K 12-31-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 000-19720 A. Full title of the p |
|
| May 31, 2016 |
Abaxis ABAXIS, INC. 10-K 3-31-2016 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as specified |
|
| May 31, 2016 |
Conflict Minerals Report For The Year Ended December 31, 2015 Exhibit 1.01 Conflict Minerals Report For The Year Ended December 31, 2015 This Conflict Minerals Report (this ?Report? or ?CMR?) of Abaxis, Inc. (?Abaxis?,? ?our,? ?us,? or ?we?), for the period from January 1, 2015 through December 31, 2015 (the ?Reporting Period?) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securitie |
|
| May 31, 2016 |
Abaxis ABAXIS, INC. SD 12-31-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3240 Whipple Road Union City, CA 94587 (Address of principal executive offices, i |
|
| May 31, 2016 |
EX-10.27 2 ex1027.htm EXHIBIT 10.27 EXHIBIT 10.27 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. DISTRIBUTION AGREEMENT This DISTRIBUTION AGREEMENT (the “Agreement”) is made effective as of October 1, |
|
| May 31, 2016 |
Exhibit 21.1 SUBSIDIARIES OF ABAXIS, INC. The following is a list of subsidiaries of the Registrant, omitting some subsidiaries that, considered in the aggregate, would not constitute a significant subsidiary. Name Jurisdiction of Incorporation Abaxis Europe GmbH Germany Abaxis UK (formerly Quality Clinical Reagents Limited) England |
|
| May 11, 2016 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) April 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| April 28, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 22, 2016 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| April 28, 2016 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2016 and Declares a 9% Increase in Quarterly Cash Dividend Union City, California ? April 28, 2016 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufactu |
|
| April 28, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2016 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 16, 2016 |
ABAX / Abaxis, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 12)* Abaxis, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2015 (Date of Event Which |
|
| February 12, 2016 |
ABAX / Abaxis, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment SC 13G/A 1 a16-40581sc13ga.htm SC 13G/A UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0145 Washington, D.C. 20549 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . .10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Abaxis, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Numb |
|
| February 10, 2016 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 10, 2016 |
ABAX / Abaxis, Inc. / VANGUARD GROUP INC Passive Investment abaxisinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5 )* Name of issuer: Abaxis Inc Title of Class of Securities: Common Stock CUSIP Number: 002567105 Date of Event Which Requires Filing of this Statement: December 31, 2015 Check the appropriate box to designate th |
|
| February 9, 2016 |
ABAX / Abaxis, Inc. 10-Q - Quarterly Report - ABAXIS, INC. 10-Q 12-31-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2015 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as |
|
| February 9, 2016 |
ABAX / Abaxis, Inc. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08)* ABAXIS INC (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 9, 2016 |
Fifth Amendment to Lease Agreement Exhibit 10.1 Fifth Amendment to Lease Agreement This Fifth Amendment to Lease Agreement (this “Amendment”) is entered into as of December 17, 2015 (the "Effective Date"), by and among WHIPPLE ROAD HOLDINGS, LLC, a Delaware limited liability company, SFP CROSSROADS, LLC, a Delaware limited liability company, and WOODSTOCK BOWERS, LLC, a Delaware limited liability company (collectively, “Landlord”), |
|
| January 28, 2016 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2016 Declares Quarterly Cash Dividend Union City, California – January 28, 2016 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care bl |
|
| January 28, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 28, 2016 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 23, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): December 17, 2015 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2015 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant a |
|
| November 3, 2015 |
Abaxis Declares Quarterly Cash Dividend Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Declares Quarterly Cash Dividend Union City, California ? November 3, 2015 ? The Board of Directors of Abaxis, Inc. (NasdaqGS: ABAX), has declared a cash dividend of $0.11 per common share. The dividend will be payable on December 17, |
|
| November 3, 2015 |
8-K 1 form8k.htm ABAXIS, INC 8-K 10-28-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 28, 2015 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisd |
|
| October 27, 2015 |
Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2016 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2016 Union City, California – October 27, 2015 - Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and con |
|
| October 27, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 27, 2015 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 15, 2015 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 form10q.htm ABAXIS, INC. 10-Q 6-30-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2015 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-1972 |
|
| July 29, 2015 |
EXHIBIT 10.26 - 1 - Managing Director Service Agreement Between ABAXIS Europe GmbH, Peka Park, Geb?ude/Building T9 Otto-Hesse-Stra?e 19, 64293 Darmstadt, - hereinafter "Company" - here represented by its sole shareholder ABAXIS Inc. 3240 Whipple Road, Union City, CA 94587, these represented by its Chief Executive Officer Mr. Clinton H. Severson President and Chief Executive Officer and Mr. Achim H |
|
| July 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as specifie |
|
| July 23, 2015 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the First Quarter of Fiscal 2016 Declares Quarterly Cash Dividend Union City, California ? July 23, 2015 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood a |
|
| July 23, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 23, 2015 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 10, 2015 |
AMENDED AND RESTATED ABAXIS, INC. ARTICLE I EX-3.2 2 ex32.htm EXHIBIT 3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ABAXIS, INC. ARTICLE I OFFICES Section 1.1 Principal Executive Office. The principal executive office for the transaction of the business of the corporation shall be at such place inside or outside the State of California as the Board of Directors may determine from time to time. Section 1.2 Other Offices. Branch or subordin |
|
| July 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): July 6, 2015 ABAXIS, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No.) ( |
|
| July 6, 2015 |
ABAX / Abaxis, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. . . . . . . 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Abaxis, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) June 30, 2015 (Date of Event Which Re |
|
| June 29, 2015 |
Abaxis ABAXIS, INC 11-K 12-31-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One:) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-19720 A. Full title of the plan |
|
| June 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K 10-K 1 form10k.htm ABAXIS INC 10-K 3-31-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2015 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, |
|
| June 1, 2015 |
EX-1.01 2 ex1-01.htm EXHIBIT 1.01 Exhibit 1.01 Abaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2014 This report for the period from January 1, 2014 through December 31, 2014 (the “Reporting Period”) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement |
|
| June 1, 2015 |
Exhibit 21.1 SUBSIDIARIES OF ABAXIS, INC. The following is a list of subsidiaries of the Registrant, omitting some subsidiaries that, considered in the aggregate, would not constitute a significant subsidiary. Name Jurisdiction of Incorporation Abaxis Europe GmbH Germany Abaxis UK (formerly Quality Clinical Reagents Limited) England Trio Diagnostics (Ireland) Ltd England |
|
| June 1, 2015 |
EX-10.25 2 ex1025.htm EXHIBIT 10.25 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Exhibit 10.25 ASSET PURCHASE AGREEMENT between ABAXIS, INC. and ANTECH DIAGNOSTICS, INC. dated as of March 18, 2015 TABL |
|
| June 1, 2015 |
Abaxis ABAXIS INC SD 12-31-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3240 Whipple Road Union City, CA 94587 (Address of principal executive offices, i |
|
| May 4, 2015 |
Financial Statements and Exhibits 8-K 1 form8k.htm ABAXIS INC 8-K 4-28-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 28, 2015 ABAXIS, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdicti |
|
| May 4, 2015 |
(To be signed on the Transition Date.) EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 May 1, 2015 VIA HAND DELIVERY Alberto Santa Ines Abaxis, Inc. Corporate Headquarters 3240 Whipple Road, Union City, CA 94587 Phone: 510.675.6500 Fax: 510.441.6150 www.abaxis.com Abaxis Europe GmbH Otto-Hesse-Strasse 19 T9, 3. OG Ost D-64293 Darmstadt Germany Phone +.49.6151.350790 Fax +.49.6151.3507911 3240 Whipple Road Union City, CA 94587 Re: Transit |
|
| May 4, 2015 |
Attachment One Substitute for Payment Described in Section 5.4 of Severance Plan (Best After Tax) Exhibit 99.2 April 29, 2015 Dean Ross Taylor ### ##### ###### #########, ## ##### Corporate Headquarters 3240 Whipple Road, Union City, CA 94587 Phone: 510.675.6500 Fax: 510.441.6150 www.abaxis.com Abaxis Europe GmbH Otto-Hesse-Strasse 19 T9, 3. OG Ost D-64293 Darmstadt Germany Phone +.49.6151.350790 Fax +.49.6151.3507911 Dear Ross: As we have discussed, the Board of Directors of Abaxis, Inc. (the |
|
| April 30, 2015 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson, Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz 510-675-6500 602-889-9700 Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend Union City, California ? April 30, 2015 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufactur |
|
| April 30, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 30, 2015 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 20, 2015 |
VCA Inc. to Acquire Reference Laboratory Division (AVRL) from Abaxis, Inc. Exhibit 99.1 Contact: Abaxis, Inc. VCA Inc. Ross Taylor Tom Fuller Vice President, Business Development Chief Financial Officer and Vice President & Investor Relations 310-571-6500 510-675-6500 Lytham Partners, LLC Joe Dorame, Robert Blum and Joe Diaz 602-889-9700 VCA Inc. to Acquire Reference Laboratory Division (AVRL) from Abaxis, Inc. Union City, California – March 19, 2015 – Abaxis, Inc. (Nasd |
|
| March 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): March 19, 2015 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| February 13, 2015 |
ABAX / Abaxis, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G/A Passive Investment SC 13G/A 1 a15-43691sc13ga.htm SC 13G/A OMB APPROVAL OMB Number: 3235-0145 UNITED STATES Expires: February 28, 2009 SECURITIES AND EXCHANGE COMMISSION Estimated average burden Washington, D.C. 20549 hours per response. . . . . . . . 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Abaxis, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Num |
|
| February 11, 2015 |
ABAX / Abaxis, Inc. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 07)* ABAXIS, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2015 |
ABAX / Abaxis, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 abaxisinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Abaxis Inc Title of Class of Securities: Common Stock CUSIP Number: 002567105 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 9, 2015 |
Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Exhibit 10.3 Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Abaxis, Inc. (the ?Company?) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the ?Award?). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the ?Grant Notice?), in the Restricted S |
|
| February 9, 2015 |
Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Exhibit 10.2 Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Abaxis, Inc. (the ?Company?) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the ?Award?). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the ?Grant Notice?), in the Restricted S |
|
| February 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2014 or ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as |
|
| February 5, 2015 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 5, 2015 |
ABAX / Abaxis, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 11)* Abaxis, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2014 (Date of Event Which |
|
| January 29, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 29, 2015 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 29, 2015 |
Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2015 Declares Quarterly Cash Dividend Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2015 Declares Quarterly Cash Dividend Union City, California – January 29, 2015 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analy |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 form10q.htm ABAXIS, INC 10-Q 9-30-2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000- |
|
| October 28, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 22, 2014 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| October 28, 2014 |
Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Exhibit 10.3 Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Abaxis, Inc. (the “Company”) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”), in the Restricted S |
|
| October 28, 2014 |
Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Exhibit 10.2 Abaxis, Inc. Restricted Stock Unit Award Grant Notice 2014 Equity Incentive Plan Abaxis, Inc. (the “Company”) hereby awards to Participant the number of Restricted Stock Units specified and on the terms set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the “Grant Notice”), in the Restricted S |
|
| October 23, 2014 |
Abaxis Declares Quarterly Cash Dividend Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Declares Quarterly Cash Dividend Union City, California – October 23, 2014 – The Board of Directors of Abaxis, Inc. (NasdaqGS: ABAX), has declared a cash dividend of $0.10 per common share. The dividend will be payable on December 16, |
|
| October 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 22, 2014 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| October 22, 2014 |
ABAX / Abaxis, Inc. S-8 POS - - ABAXIS, INC S-8 POS 10-22-2014 As Filed with the Securities and Exchange Commission on October 22, 2014 Registration No. |
|
| October 22, 2014 |
Exhibit 99.2 ABAXIS, INC. 2014 EQUITY INCENTIVE PLAN Abaxis, Inc. 2014 Equity Incentive Plan Adopted by the Board of Directors: July 23, 2014 Approved by the Shareholders: October 22, 2014 1. General. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Abaxis, Inc. 2005 Equity Incentive Plan, as amended (the “Prior Plan”). Following the |
|
| October 22, 2014 |
ABAX / Abaxis, Inc. S-8 - - ABAXIS, INC S-8 10-22-2014 As Filed with the Securities and Exchange Commission on October 22, 2014 Registration No. |
|
| October 21, 2014 |
Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 Union City, California – October 21, 2014 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported fina |
|
| October 21, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 21, 2014 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 23, 2014 |
ABAX / Abaxis, Inc. DEF 14A - - ABAXIS INC DEF 14A 10-22-2014 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 21, 2014 |
RELEASE (To be signed on the Transition Date.) Exhibit 10.1 Corporate Headquarters 3240 Whipple Road, Union City, CA 94587 Phone: 510.675.6500 Fax: 510.441.6150 www.abaxis.com August 15, 2014 VIA HAND DELIVERY Vladimir Ostoich Abaxis Europe GmbH Otto-Hesse-Strasse 19 T9, 3. OG Ost D-64293 Darmstadt Germany Phone +.49.6151.350790 Fax +.49.6151.3507911 3240 Whipple Road Union City, CA 94587 Re: Transition/Separation Agreement Dear Vlad: Abaxis, |
|
| August 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): August 15, 2014 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No. |
|
| August 11, 2014 |
Attachment One Substitute for Payment Described in Section 5.4 of Severance Plan (Best After Tax) Exhibit 10.1 ABAXIS Corporate Headquarters 3240 Whipple Road, Union City, CA 94587 Phone: 510.675.6500 Fax: 510.441.6150 www.abaxis.com Abaxis Europe GmbH Otto-Hesse-Strasse 19 T9, 3. OG Ost D-64293 Darmstadt Germany Phone +.49.6151.350790 Fax +.49.6151.3507911 May 1, 2014 Craig Tockman, DVM #### ####### #### #########, ## ##### Dear Craig: As we have discussed, the Board of Directors of Abaxis, I |
|
| August 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as spe |
|
| July 29, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?K/A (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as specifie |
|
| July 29, 2014 |
EXHIBIT 21.1 Exhibit Index Exhibit No. Description of Document 3.1 Amended and Restated Articles of Incorporation, as amended (filed with the Securities and Exchange Commission on May 30, 2014 as Exhibit 3.1 to our Annual Report on Form 10-K for the fiscal year ended March 31, 2014 and incorporated herein by reference). 3.2 By-laws, as amended (filed with the Securities and Exchange Commission on |
|
| July 24, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 24, 2014 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 24, 2014 |
Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 Declares Quarterly Cash Dividend Union City, California – July 24, 2014 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood an |
|
| June 27, 2014 |
ABAX / Abaxis, Inc. 11-K - - ABAXIS INC 11-K 12-31-2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One:) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-19720 A. Full title of the plan |
|
| June 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3240 Whipple Road Union City, CA 94587 (Address of principal executive offices, i |
|
| June 2, 2014 |
Exhibit 1.02 Abaxis, Inc. Conflict Minerals Report For The Year Ended December 31, 2013 This report for the period from January 1, 2013 through December 31, 2013 (the “Reporting Period”) is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement reporting and disclosure requireme |
|
| May 30, 2014 |
EXHIBIT 21.1 SUBSIDIARIES OF ABAXIS, INC. Name Jurisdiction of Incorporation Abaxis Europe GmbH Germany |
|
| May 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as specified |
|
| May 30, 2014 |
AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ABAXIS, INC. EXHIBIT 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ABAXIS, INC. Richard K. Leute and Gary H. Stroy certify that: 1. They are the duly elected and acting President and Secretary, respectively, of Abaxis, Inc., a California corporation (the "Corporation"). 2. The Articles of Incorporation of the Corporation are amended and restated to read in their entirety as follows: "ARTICLE I The name |
|
| May 30, 2014 |
EXHIBIT 3.2 BY-LAWS OF ABAXIS, INC. ARTICLE I OFFICES Section 1.1 Principal Executive Office. The principal executive office for the transaction of the business of the corporation is hereby fixed and located at 265 North Whisman Avenue, Mountain View, County of Santa Clara, State of California. The Board of Directors is hereby granted full power and authority to change said principal office from o |
|
| May 28, 2014 |
- ABAXIS, INC POS AM 5-28-2014 (333-98475) As filed with the Securities and Exchange Commission on May 28, 2014 Registration Nos. |
|
| May 28, 2014 |
- ABAXIS, INC POS AM 5-28-2014 (333-69999) As filed with the Securities and Exchange Commission on May 28, 2014 Registration Nos. |
|
| May 28, 2014 |
- ABAXIS, INC POS AM 5-28-2014 (333-53484) As filed with the Securities and Exchange Commission on May 28, 2014 Registration Nos. |
|
| April 29, 2014 |
- ABAXIS, INC 8-K 4-23-2014 (ITEM 5.02) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 23, 2014 ABAXIS, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| April 24, 2014 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2014; Declares Quarterly Cash Dividend Union City, California – April 24, 2014 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company |
|
| April 24, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 23, 2014 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 18, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 15, 2014 ABAXIS, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| April 18, 2014 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 NOTICE OF PENDENCY OF CLASS AND DERIVATIVE ACTION, PROPOSED SETTLEMENT OF CLASS AND DERIVATIVE ACTION AND SETTLEMENT HEARING AND RIGHT TO APPEAR TO: ALL PERSONS OR ENTITIES WHO HELD SHARES OF THE COMMON STOCK OF ABAXIS, INC. (“ABAXIS” OR THE “COMPANY”) AS OF THE CLOSE OF BUSINESS ON AUGUST 31, 2012 (THE “RECORD DATE”), either of record or beneficially, |
|
| February 13, 2014 |
ABAX / Abaxis, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 10)* Abaxis, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2013 (Date of Event Which |
|
| February 12, 2014 |
ABAX / Abaxis, Inc. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 06)* ABAXIS, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2014 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) January 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2014 |
ABAX / Abaxis, Inc. / VANGUARD GROUP INC Passive Investment abaxisinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Abaxis Inc Title of Class of Securities: Common Stock CUSIP Number: 002567105 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designate th |
|
| February 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2013 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as |
|
| February 10, 2014 |
ABAX / Abaxis, Inc. / PRIMECAP MANAGEMENT CO/CA/ - SC 13G Passive Investment SC 13G 1 a14-53591sc13g.htm SC 13G OMB APPROVAL UNITED STATES OMB Number: 3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires: February 28, 2009 Washington, D.C. 20549 Estimated average burden hours per response. . . . . . . . 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Abaxis, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) J |
|
| January 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 30, 2014 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 30, 2014 |
ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE THIRD QUARTER OF FISCAL 2014 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE THIRD QUARTER OF FISCAL 2014 Union City, California – January 30, 2014 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported |
|
| January 13, 2014 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2013 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of |
|
| November 12, 2013 |
AMENDMENT TO EXCLUSIVE AGREEMENT Exhibit 10.1 AMENDMENT TO EXCLUSIVE AGREEMENT THIS AMENDMENT (this ?Amendment?') of that certain Exclusive Agreement, dated as of October 26, 2012 (?Original Agreement?), by and between Abbott Point of Care Inc. and Abaxis, Inc., is effective as of September 30, 2013 (?Amendment Effective Date?). Capitalized terms used but not defined herein have the meanings given them in the Original Agreement. |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2013 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant a |
|
| October 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 23, 2013 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| October 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 22, 2013 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 22, 2013 |
ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE SECOND QUARTER OF FISCAL 2014 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE SECOND QUARTER OF FISCAL 2014 Union City, California – October 22, 2013 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reporte |
|
| September 20, 2013 |
- ABAXIS, INC DEF 14A 10-23-2013 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2013 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as spe |
|
| August 9, 2013 |
[* ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. |
|
| July 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 25, 2013 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 25, 2013 |
ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE FIRST QUARTER OF FISCAL 2014 EX-99.1 2 ex991.htm EXHIBIT 99.1 EXHIBIT 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE FIRST QUARTER OF FISCAL 2014 Union City, California – July 25, 2013 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood an |
|
| July 2, 2013 |
[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. |
|
| July 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2012 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant |
|
| June 21, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (Mark One:) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-19720 A. Full title of the plan |
|
| June 14, 2013 |
EXHIBIT 21.1 SUBSIDIARIES OF ABAXIS, INC. Name Jurisdiction of Incorporation Abaxis Europe GmbH Germany |
|
| June 14, 2013 |
ABAXIS, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS EX-10.8 3 ex108.htm EXHIBIT 10.8 Exhibit 10.8 ABAXIS, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Participant has been granted an award of Restricted Stock Units (the “Award”) pursuant to the Abaxis, Inc. 2005 Equity Incentive Plan (the “Plan”), each of which represents the right to receive on the applicable Settlement Date one share of Common Stock of Abaxis, Inc., as follows: Participant: |
|
| June 14, 2013 |
ABAXIS, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS EX-10.7 2 ex107.htm EXHIBIT 10.7 Exhibit 10.7 ABAXIS, INC. NOTICE OF GRANT OF RESTRICTED STOCK UNITS The Participant has been granted an award of Restricted Stock Units (the “Award”) pursuant to the Abaxis, Inc. 2005 Equity Incentive Plan (the “Plan”), each of which represents the right to receive on the applicable Settlement Date one (1) Share of Abaxis, Inc., as follows: Participant: Date of Gra |
|
| June 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as specified |
|
| June 4, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| April 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): April 24, 2013 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No.) |
|
| April 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 25, 2013 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 25, 2013 |
ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE FOURTH QUARTER AND FISCAL 2013 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE FOURTH QUARTER AND FISCAL 2013 Union City, California – April 25, 2013 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported |
|
| February 22, 2013 |
ABAX / Abaxis, Inc. / VANGUARD GROUP INC Passive Investment abaxisinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Abaxis Inc Title of Class of Securities: Common Stock CUSIP Number: 002567105 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate th |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 77-0213001 (State of Incorporation) (I.R.S. Employer Identification No.) 3240 Whipple Road Union City, California 94587 (Address of principal executive offices) Abaxis, Inc. 2005 Equit |
|
| February 14, 2013 |
ABAX / Abaxis, Inc. / Neuberger Berman Group LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* ABAXIS, Inc. (Name of Issuer) Common (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 14, 2013 |
ABAX / Abaxis, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 9)* Abaxis, Inc. (Name of Issuer) Common Stock, No Par Value (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2012 (Date of Event Which R |
|
| February 11, 2013 |
[ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. |
|
| February 11, 2013 |
ABAXIS, INC. 2005 EQUITY INCENTIVE PLAN Table of Contents Exhibit 10.4 ABAXIS, INC. 2005 EQUITY INCENTIVE PLAN Table of Contents Page 1. ESTABLISHMENT, PURPOSE AND TERM OF PLAN A-1 1.1 Establishment A-1 1.2 Purpose A-1 1.3 Term of Plan A-1 2. DEFINITIONS AND CONSTRUCTION A-1 2.1 Definitions A-1 2.2 Construction A-7 3. ADMINISTRATION A-7 3.1 Administration by the Committee A-7 3.2 Administration with Respect to Insiders A-7 3.3 Committee Complying with Se |
|
| February 11, 2013 |
ABAX / Abaxis, Inc. / VANGUARD GROUP INC Passive Investment abaxisinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Abaxis Inc Title of Class of Securities: Common Stock CUSIP Number: 002567105 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate th |
|
| February 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2012 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant as |
|
| February 5, 2013 |
ABAX / Abaxis, Inc. / KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC - NONE Passive Investment SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* ABAXIS Inc (Name of Issuer) Common Stock (Title of Class of Securities) 002567105 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| January 31, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 31, 2013 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 31, 2013 |
ABAXIS REPORTS RECORD REVENUES FOR THE THIRD QUARTER OF FISCAL 2013 EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 ABAXIS REPORTS RECORD REVENUES FOR THE THIRD QUARTER OF FISCAL 2013 Union City, California – January 31, 2013 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analy |
|
| December 7, 2012 |
Abaxis Declares Special Cash Dividend of $1.00 Per Share EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Declares Special Cash Dividend of $1.00 Per Share Union City, California – December 6, 2012 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems |
|
| December 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): December 6, 2012 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| November 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): November 8, 2012 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| November 9, 2012 |
CONFIDENTIAL SETTLEMENT AGREEMENT Exhibit 10.1 [ ***] = Certain confidential information contained in this document, marked by brackets and asterisks, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with respect to the omitted information CONFIDENTIAL SETTLEMENT AGREEMENT This CONFI |
|
| November 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 or o Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 000-19720 ABAXIS, INC. (Exact name of registrant a |
|
| November 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 26, 2012 ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| November 1, 2012 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Announces Exclusive Distribution Agreement with Abbott Abbott to market, sell and distribute the Piccolo® Xpress and its reagent discs for point-of-care blood chemistry analysis in the human medical mar |
|
| October 26, 2012 |
- ABAXIS INC DEFA 14A 10-24-2012 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| October 26, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 24, 2012 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| October 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): October 23, 2012 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File No |
|
| October 23, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 23, 2012 Date of Report (Date of Earliest Event Reported): ABAXIS, INC. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 23, 2012 |
ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE SECOND QUARTER OF FISCAL 2013 Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 ABAXIS REPORTS FINANCIAL PERFORMANCE FOR THE SECOND QUARTER OF FISCAL 2013 Union City, California – October 23, 2012 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reporte |
|
| September 27, 2012 |
Abaxis Announces Settlement of Patent Litigation With Cepheid Exhibit 99.1 Contact: Abaxis, Inc. Lytham Partners, LLC Clint Severson Joe Dorame, Robert Blum and Joe Diaz Chief Executive Officer 602-889-9700 510-675-6500 Abaxis Announces Settlement of Patent Litigation With Cepheid Union City, California – September 26, 2012 - Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point of care instruments and consumables for the medical, res |
|
| September 27, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (date of earliest event reported): September 24, 2012 Abaxis, Inc. (Exact name of registrant as specified in its charter) California 000-19720 77-0213001 (State or other jurisdiction of incorporation) (Commission File |
